Sérgio Castedo

ORCID: 0000-0003-0582-5178
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Genetic factors in colorectal cancer
  • Testicular diseases and treatments
  • Genomic variations and chromosomal abnormalities
  • Sarcoma Diagnosis and Treatment
  • Thyroid Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • Neuroblastoma Research and Treatments
  • Cancer-related Molecular Pathways
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Prenatal Screening and Diagnostics
  • Helicobacter pylori-related gastroenterology studies
  • Chromosomal and Genetic Variations
  • Hedgehog Signaling Pathway Studies
  • DNA Repair Mechanisms
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Renal and related cancers
  • Genetic Syndromes and Imprinting
  • Sexual Differentiation and Disorders
  • Cardiac electrophysiology and arrhythmias
  • Ovarian cancer diagnosis and treatment
  • Cancer-related gene regulation
  • Gastrointestinal Tumor Research and Treatment
  • Ion channel regulation and function
  • Renal cell carcinoma treatment

Universidade do Porto
2003-2023

Hospital de São João
1990-2023

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2018-2023

University of Manchester
2022-2023

Centro de Genética Clínica
1990-2014

Instituto Português de Oncologia Francisco Gentil
1990-2006

University of Groningen
1988-2000

Instituto Português de Oncologia de Coimbra Francisco Gentil
2000

IPO Porto
1998-2000

University of the Basque Country
1997

We report the association of <i>CDH1/E-cadherin</i> mutations with cleft lip, or without palate (CLP), in two families hereditary diffuse gastric cancer (HDGC). In each family, <i>CDH1</i> mutation was a splicing generating aberrant transcripts an in-frame deletion, removing extracellular cadherin repeat domains involved cell-cell adhesion. Such might encode mutant proteins trans-dominant negative effects. found that is highly expressed at 4 and 5 weeks frontonasal prominence, 6 lateral...

10.1136/jmg.2005.031385 article EN Journal of Medical Genetics 2005-04-15

The ultrasonographic measurement of nuchal translucency thickness at 10-13 weeks gestation is accepted as an efficient method screening for chromosomal abnormalities. However, the underlying mechanism producing increased still poorly understood. purpose this study was to investigate possible contribution impaired cardiac function such increase, by studying venous return in ductus venosus, using Doppler ultrasound. In a total 65 fetuses, measured means transvaginal probe. Color-coded and...

10.1046/j.1469-0705.1997.10040265.x article EN Ultrasound in Obstetrics and Gynecology 1997-10-01

Microsatellite instability (MSI) is a major pathway involved in gastric carcinogenesis occurring 20% of cancer (GC). However, it not clear whether MSI phenotype preferentially occurs the sporadic or familial GC, when stringent inclusion criteria are used. The aim this study was to compare frequency and hypermethylation MLH1 promoter large series GC patients (non-HNPCC non-CDH1-related) cases. Additionally, we analysed immunoexpression MMR proteins fraction Overall, 7.1%, hereditary tumours...

10.1002/ijc.25495 article EN International Journal of Cancer 2010-06-07

10.1016/s1470-2045(22)00643-x article EN cc-by-nc-nd The Lancet Oncology 2022-11-25

Background. The authors previously described a large pedigree with familial gastric polyposis and high incidence of cancer demonstrated the autosomal dominant pattern inheritance. current study histologic immunohistologic features lesions in an attempt to clarify mechanisms underlying carcinogenesis this family. Methods. studied histopathologic histochemical several specimens nine members family searched for expression carcinoembryonic antigen (CEA), p21 protein (ras oncogene), p53 (p53...

10.1002/1097-0142(19930715)72:2<323::aid-cncr2820720204>3.0.co;2-g article EN Cancer 1993-07-15

Abstract Loss of heterozygosity (LOH) affecting the long arm chromosome 6 has been found repeatedly in human cancers. Recently, our group reported that del(6)(q21‐22→qter) was most consistent structural cytogenetic abnormality gastric carcinomas. To determine more precisely deleted region, we studied 51 tumors with 9 polymorphic markers on this arm. LOH one or 39% tumors. at region 6q22.3 detected 50% informative and 6q26‐q27 37% By comparative analysis regions, identified two separate...

10.1002/gcc.2870140106 article EN Genes Chromosomes and Cancer 1995-09-01

Red cell distribution width (RDW), a classical parameter used in the differential diagnosis of anemia, has recently been recognized as marker chronic inflammation and high levels oxidative stress (OS). Fanconi anemia (FA) is genetic disorder associated to redox imbalance dysfunctional response OS. Clinically, it characterized by progressive bone marrow failure, which remains primary cause morbidity mortality. Macrocytosis increased fetal hemoglobin, two indicators erythropoiesis, are...

10.1186/s13023-016-0485-0 article EN cc-by Orphanet Journal of Rare Diseases 2016-07-25

Abstract We report the cytogenetic analysis of a follicular thyroid carcinoma and its bone metastasis. Both lesions had identical chromosomal abnormalities, with der(3)t(2;3)(q13;p25) as most likely primary clonal alteration. Our findings corroborate previous observations frequent 3p deletions in carcinomas suggest that minimal region loss these tumors is 3p25→pter. © 1993 Wiley‐Liss, Inc.

10.1002/gcc.2870080311 article EN Genes Chromosomes and Cancer 1993-11-01

Abstract Background The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some do not respond therapy. Our goals were investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel cisplatin resistance. Methods Thirty-four with primary carcinomas (26 serous eight clear cell carcinomas) treated paclitaxel/cisplatin analysed. exon 4...

10.1186/1471-2407-5-101 article EN cc-by BMC Cancer 2005-08-11
Coming Soon ...